Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Lung cancer remains the leading cause of cancer deaths in the United States. In the past
decade, significant advances have been made in the science of non–small cell lung cancer …

Focal radiation therapy enhances systemic responses to anti-CTLA-4 antibodies in
preclinical studies and in some patients with melanoma,–, but its efficacy in inducing …

Background In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …

Abstract Treatment with immune checkpoint inhibitors (ICPIs) extends survival in a
proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number …

Importance Checkpoint inhibitors have replaced docetaxel as the new standard second-line
therapy in advanced non–small cell lung carcinoma (NSCLC), but little is known about the …

Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …

Introduction We performed a meta-analysis to assess the role of immune checkpoint
inhibitors as second-line therapy in EGFR-mutant advanced NSCLC. Methods Randomized …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …